1.
The Scottish Intercollegiate Guidelines Network website is at http://www.sign.ac.uk. http://www.sign.ac.uk/
2.
The American Diabetes Association. https://www.diabetes.org/
3.
The Cochrane collaboration at http://www.cochrane.org/ helps "healthcare practitioners, policy-makers, patients, their advocates and carers make well-informed decisions about health care, by preparing, updating, and promoting the accessibility of Cochrane Reviews.”. http://www.cochrane.org/
4.
NHS Evidence, an offshoot of NICE, provides basic information on evidence-based management of many common conditions, including diabetes, and can be found at https://www.evidence.nhs.uk/. https://www.evidence.nhs.uk/
5.
The commercial but not-for-profit Trip database at http://www.tripdatabase.com claims to be "the internet’s premier source of evidence-based content”. http://www.tripdatabase.com/
6.
The International Diabetes Federation (IDF) is at http://www.idf.org. http://www.idf.org/
7.
The George Eliot Diabetes Care Team’s Alphabet Strategy website is at www.abcdiabetes.co.uk. http://www.abcdiabetes.co.uk/
8.
The Critical Appraisal Skills Programme (CASP) critical appraisal checklists can be downloaded from http://www.casp-uk.net/. https://casp-uk.net/casp-tools-checklists/
9.
Essential Values-Based Practice is supported by a website jointly hosted by Cambridge University Press and Warwick Medical School at http://www.go.warwick.ac.uk/values-basedpractice. http://valuesbasedpractice.org/
10.
The European Association for the Study of Diabetes (EASD). http://www.easd.org/
11.
Diabetes Care: 40 (Supplement 1). Diabetes Care. 2017;40(Supplement 1). https://0-care-diabetesjournals-org.pugwash.lib.warwick.ac.uk/content/40/Supplement_1
12.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720
13.
Fralick M, Schneeweiss S, Patorno E. Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. New England Journal of Medicine. 2017;376(23):2300-2302. http://0-www.nejm.org.pugwash.lib.warwick.ac.uk/doi/full/10.1056/NEJMc1701990
14.
Effects of Liraglutide on Glycemic Control :Cleveland Clinic Journal of Medicine. Published online 2015. http://www.mdedge.com/ccjm/clinical-edge/summary/obesity/effects-liraglutide-glycemic-control
15.
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine. 2017;(377):644-657. http://0-www.nejm.org.pugwash.lib.warwick.ac.uk/doi/full/10.1056/NEJMoa1611925#t=article
16.
Nauck MA. A Critical Analysis of the Clinical Use of Incretin-Based Therapies: The benefits by far outweigh the potential risks. Diabetes Care. 2013;36(7):2126-2132. doi:10.2337/dc12-2504
17.
Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine. 2013;369(14):1317-1326. doi:10.1056/NEJMoa1307684
18.
Lipska KJ, Krumholz H, Soones T, Lee SJ. Polypharmacy in the Aging Patient. JAMA. 2016;315(10). doi:10.1001/jama.2016.0299
19.
Caverly TJ, Fagerlin A, Zikmund-Fisher BJ, et al. Appropriate Prescribing for Patients With Diabetes at High Risk for Hypoglycemia. JAMA Internal Medicine. Published online 26 October 2015. doi:10.1001/jamainternmed.2015.5950
20.
Sinclair AJ, Bode B, Harris S, et al. Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis. Journal of the American Geriatrics Society. 2016;64(3):543-552. doi:10.1111/jgs.14028
21.
Hine J, Paterson H, Abrol E, Russell-Jones D, Herring R. SGLT inhibition and euglycaemic diabetic ketoacidosis. The Lancet Diabetes & Endocrinology. 2015;3(7):503-504. http://0-www.sciencedirect.com.pugwash.lib.warwick.ac.uk/science/article/pii/S2213858715002260?via%3Dihub
22.
Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. New England Journal of Medicine. 2016;375(4):323-334. doi:10.1056/NEJMoa1515920
23.
Scheen AJ. SGLT2 Inhibitors: Benefit/Risk Balance. Current Diabetes Reports. 2016;16(10). doi:10.1007/s11892-016-0789-4
24.
Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovascular Diabetology. 2015;14(1). doi:10.1186/s12933-015-0260-x
25.
Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. The Lancet. Published online December 2015. doi:10.1016/S0140-6736(15)01225-8
26.
Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials. Diabetes and Vascular Disease Research. 2015;12(2):90-100. doi:10.1177/1479164114559852
27.
Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141
28.
Filippatos TD, Tsimihodimos V, Elisaf MS. Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors. Expert Opinion on Pharmacotherapy. 2016;17(12):1581-1583. http://0-www.tandfonline.com.pugwash.lib.warwick.ac.uk/doi/full/10.1080/14656566.2016.1201073
29.
Dauriz M, Targher G, Laroche C, et al. Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term Registry. Diabetes Care. 2017;40(5):671-678. doi:10.2337/dc16-2016
30.
Wu JHY, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. The Lancet Diabetes & Endocrinology. 2016;4(5):411-419. doi:10.1016/S2213-8587(16)00052-8
31.
Filippatos TD, Tsimihodimos V, Elisaf MS. Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors. Expert Opinion on Pharmacotherapy. 2016;17(12):1581-1583. http://0-www.tandfonline.com.pugwash.lib.warwick.ac.uk/doi/full/10.1080/14656566.2016.1201073
32.
Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141
33.
Maruthur NM, Tseng E, Hutfless S, et al. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes. Annals of Internal Medicine. 2016;164(11). doi:10.7326/M15-2650
34.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720
35.
Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. New England Journal of Medicine. 2015;373(23):2247-2257. https://0-www-proquest-com.pugwash.lib.warwick.ac.uk/docview/2119957013/EA851E49618490DPQ/1?accountid=14888
36.
Kosiborod M, Cavender MA, Fu AZ, et al. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering DrugsClinical Perspective. Circulation. 2017;136(3):249-259. https://0-www-ncbi-nlm-nih-gov.pugwash.lib.warwick.ac.uk/pubmed/28522450
37.
Pieber TR, Marso SP, McGuire DK, et al. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia. 2018;61(1):58-65. https://0-link-springer-com.pugwash.lib.warwick.ac.uk/article/10.1007/s00125-017-4422-0
38.
Zeitler P, Fu J, Tandon N, et al. Type 2 diabetes in child and adolescent. Pediatric Diabetes. 2014;15:26-46. http://0-onlinelibrary.wiley.com.pugwash.lib.warwick.ac.uk/doi/10.1111/pedi.12179/epdf
39.
Pediatric Diabetes. 15(S20). http://onlinelibrary.wiley.com/doi/10.1111/pedi.2014.15.issue-S20/issuetoc
40.
Bangstad HJ, Danne T, Deeb L, Jarosz-Chobot P, Urakami T, Hanas R. Insulin treatment in children and adolescents with diabetes. Pediatric Diabetes. 2009;10(6):82-99. doi:10.1111/j.1399-5448.2009.00578.x
41.
ABIOLA D, SATHYAPALAN T, HEPBURN D. Management of type 1 and type 2 diabetes requiring insulin. Prescriber. Published online 2016. http://www.prescriber.co.uk/article/management-type-1-type-2-diabetes-requiring-insulin/
42.
ABIOLA D, SATHYAPALAN T, HEPBURN D. Management of type 1 and type 2 diabetes requiring insulin. Prescriber. Published online 2016. http://www.prescriber.co.uk/article/management-type-1-type-2-diabetes-requiring-insulin/
43.
Rang H. Pharmacokinetics. In: Rang & Dale’s Pharmacology. 7th ed. Elsevier/Churchill Livingstone; 2012:123-131. https://contentstore.cla.co.uk/secure/link?id=1d4bfbd8-c343-e611-80bd-0cc47a6bddeb
44.
Fadini GP, Bonora BM, Avogaro A. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia. 2017;60(8):1385-1389. https://0-link-springer-com.pugwash.lib.warwick.ac.uk/article/10.1007/s00125-017-4301-8
45.
Young LA, Buse JB, Weaver MA, et al. Glucose Self-monitoring in Non–Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings. JAMA Internal Medicine. 2017;177(7). doi:10.1001/jamainternmed.2017.1233
46.
The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. New England Journal of Medicine. 2008;358(24):2545-2559. https://0-www-proquest-com.pugwash.lib.warwick.ac.uk/docview/223930983?accountid=14888
47.
Crowley MJ, Diamantidis CJ, McDuffie JR, et al. Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease. Annals of Internal Medicine. 2017;166(3). doi:10.7326/M16-1901
48.
Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2015;373(3):232-242. https://0-www-proquest-com.pugwash.lib.warwick.ac.uk/docview/1696912909?accountid=14888
49.
Marso SP, McGuire DK, Zinman B, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. New England Journal of Medicine. Published online 2017. https://0-www-proquest-com.pugwash.lib.warwick.ac.uk/docview/1931756550?accountid=14888
50.
Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine. 2013;369(14):1317-1326. https://0-www-nejm-org.pugwash.lib.warwick.ac.uk/doi/full/10.1056/NEJMoa1307684
51.
Gæde P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes. New England Journal of Medicine. 2008;358(6):580-591. https://0-www-proquest-com.pugwash.lib.warwick.ac.uk/docview/223923658?accountid=14888
52.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720
53.
Gæde P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 2016;59(11):2298-2307. doi:10.1007/s00125-016-4065-6
54.
The ADVANCE Collaborative Group. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2008;358(24):2560-2572. https://0-www-proquest-com.pugwash.lib.warwick.ac.uk/docview/223924651/fulltextPDF/4EC80B054DE144D4PQ/1?accountid=14888
55.
Chen L, Pei JH, Kuang J, et al. Effect of lifestyle intervention in patients with type 2 diabetes: A meta-analysis. Metabolism. 2015;64(2):338-347. http://www.metabolismjournal.com/article/S0026-0495(14)00312-6/fulltext
56.
Ismail K, Winkley K, Rabe-Hesketh S. Systematic review and meta-analysis of randomised controlled trials of psychological interventions to improve glycaemic control in patients with type 2 diabetes. The Lancet. 2004;363(9421):1589-1597. https://0-www-sciencedirect-com.pugwash.lib.warwick.ac.uk/science/article/pii/S0140673604162028
57.
Effects of Intensive Glucose Lowering in Type 2 Diabetes. New England Journal of Medicine. 2008;358(24):2545-2559. doi:10.1056/NEJMoa0802743
58.
Vaccaro O, Masulli M, Nicolucci A, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. The Lancet Diabetes & Endocrinology. 2017;5(11):887-897. doi:10.1016/S2213-8587(17)30317-0
59.
Complications of Diabetes Mellitus | InTechOpen. https://www.intechopen.com/books/pathophysiology-and-complications-of-diabetes-mellitus